All In Biotech

NDA 020333 · Takeda Pharms USA

Agrylin

Anagrelide Hydrochloride · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Oct 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Mar 14, 1997

Approved uses

3

Original approval plus efficacy supplements

Registered trials

24

11 Phase 3, 0 recruiting

FAERS reports

1,175

946 serious, 128 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 8, 2026.

AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 )

Mechanism: The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • AGRYLIN · ANAGRELIDE HYDROCHLORIDE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • AGRYLIN · ANAGRELIDE HYDROCHLORIDE EQ 1MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Anagrelide" as an intervention, any sponsor and status, largest first.

All 24 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use82
  • anaemia63
  • platelet count increased60
  • cerebral infarction51
  • headache46
  • fatigue45
  • diarrhoea42
  • dizziness41
  • myelofibrosis41
  • haemoglobin decreased38
  • nausea36
  • asthenia34

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200433
200542
200632
200722
200831
200918
201012
201158
201255
201317
201417
201534
201642
201772
201882
2019105
202087
202180
202267
2023100
202465
202566
202638

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Agrylin (Anagrelide HCl)

2024 spending

$159K

Beneficiaries

33

151 claims

Per beneficiary

$4,810

$7.92 per unit

View as table
YearSpending
2020$1,931,961
2021$552,598
2022$336,322
2023$232,260
2024$158,726

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.